- Previous Close
46.28 - Open
42.04 - Bid --
- Ask --
- Day's Range
42.04 - 47.02 - 52 Week Range
37.35 - 74.80 - Volume
9,677 - Avg. Volume
13,596 - Market Cap (intraday)
1.289B - Beta (5Y Monthly) 0.92
- PE Ratio (TTM)
20.02 - EPS (TTM)
2.26 - Earnings Date Feb 14, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Aarey Drugs & Pharmaceuticals Limited manufactures and sells active pharmaceutical ingredients, intermediates, and specialty chemicals for various industrial applications in India. The company provides mono methyl and die methyl urea, ortho para nitro anisole, 2 bromomethyl 1, and 3 dioxalane and uracile, as well as active pharma ingredients, such as metformin HCL, mefenamic acid, and doxophylline. It also offers chemicals and solvents, including aromatic chemicals, chemical acids, chlor alkalies, glycols and glycol ethers, fiber intermediates, acetates and esters, and chlorinated solvents, as well as industrial alchols, ketones, amines, oleochemicals, intermediates, olefines, phosphates, fertilizers, monomers, and chemicals. In addition, the company trades in industrial solvents and chemicals.The company's pharmaceutical products are used by pharmaceutical formulation manufacturers and pharmaceutical merchant exporters. Aarey Drugs & Pharmaceuticals Limited was incorporated in 1990 and is headquartered in Mumbai, India.
www.aareydrugs.com--
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: AAREYDRUGS.NS
View MorePerformance Overview: AAREYDRUGS.NS
Trailing total returns as of 2/13/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: AAREYDRUGS.NS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: AAREYDRUGS.NS
View MoreValuation Measures
Market Cap
1.32B
Enterprise Value
1.69B
Trailing P/E
20.45
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.24
Price/Book (mrq)
0.97
Enterprise Value/Revenue
0.33
Enterprise Value/EBITDA
12.87
Financial Highlights
Profitability and Income Statement
Profit Margin
1.10%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
4.72B
Net Income Avi to Common (ttm)
51.98M
Diluted EPS (ttm)
2.26
Balance Sheet and Cash Flow
Total Cash (mrq)
28.9M
Total Debt/Equity (mrq)
23.61%
Levered Free Cash Flow (ttm)
--